Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Bladder Cancer

  Free Subscription


Articles published in Int J Urol

Retrieve available abstracts of 100 articles:
HTML format



Single Articles


    September 2021
  1. POLIKARPOV DM, Campbell DH, Zaslavsky AB, Lund ME, et al
    Glypican-1 as a target for fluorescence molecular imaging of bladder cancer.
    Int J Urol. 2021 Sep 8. doi: 10.1111/iju.14683.
    PubMed     Abstract available


  2. NASELLI A
    Editorial Comment to Systematic review and meta-analysis of narrow band imaging for non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Sep 7. doi: 10.1111/iju.14687.
    PubMed    


    August 2021
  3. GRAVESTOCK P, Coulthard N, Veeratterapillay R, Heer R, et al
    Systematic review and meta-analysis of narrow band imaging for non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Aug 27. doi: 10.1111/iju.14671.
    PubMed     Abstract available


  4. SHINDO T, Hashimoto K, Tanaka T, Taguchi K, et al
    Therapeutic options to reduce intravesical recurrence in newly diagnosed Ta high-grade bladder cancer according to risk stratification: A multicenter retrospective study.
    Int J Urol. 2021 Aug 3. doi: 10.1111/iju.14657.
    PubMed     Abstract available


  5. SETOGUCHI K, Saito K
    Editorial Comment from Dr Setoguchi and Dr Saito to Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.
    Int J Urol. 2021;28:821-822.
    PubMed    


  6. SHIGA M, Nagumo Y, Chihara I, Nitta S, et al
    Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.
    Int J Urol. 2021;28:814-819.
    PubMed     Abstract available


  7. HATAKEYAMA S, Ohyama C
    Editorial Comment from Dr Hatakeyama and Dr Ohyama to Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.
    Int J Urol. 2021;28:820.
    PubMed    


  8. SAZUKA T
    Editorial Comment from Dr Sazuka to Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.
    Int J Urol. 2021;28:820-821.
    PubMed    


    July 2021
  9. SHIN T, Mimata H
    "Early-pull-out" technique for intracorporeal ileal conduit urinary diversion after robot-assisted radical cystectomy.
    Int J Urol. 2021;28:778-779.
    PubMed    


    May 2021
  10. FAN J, Wu K, Zhang N, Yang T, et al
    Green-light laser en bloc resection versus conventional transurethral resection for initial non-muscle-invasive bladder cancer: A randomized controlled trial.
    Int J Urol. 2021 May 19. doi: 10.1111/iju.14592.
    PubMed     Abstract available


  11. MIYATA Y, Matsuo T, Sakai H
    Editorial Comment to Green-light laser en bloc resection versus conventional transurethral resection for initial non-muscle-invasive bladder cancer: A randomized controlled trial.
    Int J Urol. 2021 May 19. doi: 10.1111/iju.14607.
    PubMed    


  12. KUROBE M
    Editorial Comment from Dr Kurobe to Telomerase reverse transcriptase promoter mutation in tumorigenesis of bladder cancer: Evolutionary trajectory by algorithmic inference from cross-sectional data.
    Int J Urol. 2021 May 3. doi: 10.1111/iju.14594.
    PubMed    


  13. IQBAL U, Durrani MM, Elsayed AS, Hussein AA, et al
    Functional outcomes after robot-assisted radical cystectomy: A review of literature.
    Int J Urol. 2021;28:493-501.
    PubMed     Abstract available


  14. FARAJ KS, Rose KM, Navaratnam AK, Abdul-Muhsin HM, et al
    Effect of intracorporeal urinary diversion on the incidence of benign ureteroenteric stricture after cystectomy.
    Int J Urol. 2021;28:593-597.
    PubMed     Abstract available


    April 2021
  15. LONATI C, Moschini M
    Editorial Comment from Dr Lonati and Dr Moschini to Impact of preoperative sarcopenia and myosteatosis on prognosis after radical cystectomy in patients with bladder cancer.
    Int J Urol. 2021 Apr 22. doi: 10.1111/iju.14577.
    PubMed    


  16. URABE F
    Editorial Comment from Dr Urabe to Telomerase reverse transcriptase promoter mutation in tumorigenesis of bladder cancer: Evolutionary trajectory by algorithmic inference from cross-sectional data.
    Int J Urol. 2021 Apr 21. doi: 10.1111/iju.14580.
    PubMed    


  17. SAITO R
    Editorial Comment from Dr Saito to Use of surgical checklist during transurethral resection increases detrusor muscle collection rate and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Apr 21. doi: 10.1111/iju.14588.
    PubMed    


  18. KIJIMA T
    Editorial Comment from Dr Kijima to Impact of preoperative sarcopenia and myosteatosis on prognosis after radical cystectomy in patients with bladder cancer.
    Int J Urol. 2021 Apr 21. doi: 10.1111/iju.14581.
    PubMed    


  19. HAYASHI Y, Fujita K, Banno E, Eich ML, et al
    Telomerase reverse transcriptase promoter mutation in tumorigenesis of bladder cancer: Evolutionary trajectory by algorithmic inference from cross-sectional data.
    Int J Urol. 2021 Apr 15. doi: 10.1111/iju.14574.
    PubMed    


  20. YAMASHITA S, Iguchi T, Koike H, Wakamiya T, et al
    Impact of preoperative sarcopenia and myosteatosis on prognosis after radical cystectomy in patients with bladder cancer.
    Int J Urol. 2021 Apr 5. doi: 10.1111/iju.14569.
    PubMed     Abstract available


    March 2021
  21. TEOH JY
    Editorial Comment to Use of surgical checklist during transurethral resection increases detrusor muscle collection rate and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Mar 28. doi: 10.1111/iju.14563.
    PubMed    


  22. HATANO K, Nonomura N
    Editorial Comment from Dr Hatano and Dr Nonomura to Temporal trends in the incidence of distant-stage bladder cancer among young individuals.
    Int J Urol. 2021 Mar 28. doi: 10.1111/iju.14559.
    PubMed    


  23. SETOGUCHI K, Saito K
    Editorial Comment from Dr Setoguchi and Dr Saito to Laparoscopic versus open radical cystectomy in 607 patients with bladder cancer: Comparative survival analysis.
    Int J Urol. 2021 Mar 27. doi: 10.1111/iju.14561.
    PubMed    


  24. FUKUSHIMA H
    Editorial Comment from Dr Fukushima to Temporal trends in the incidence of distant-stage bladder cancer among young individuals.
    Int J Urol. 2021 Mar 26. doi: 10.1111/iju.14558.
    PubMed    


  25. TAOKA R, Tsunemori H, Matsuoka Y, Kohashiguchi K, et al
    Use of surgical checklist during transurethral resection increases detrusor muscle collection rate and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Mar 19. doi: 10.1111/iju.14548.
    PubMed     Abstract available


  26. HAYAKAWA N, Kikuchi E
    Editorial Comment to Effect of optimal neoadjuvant chemotherapy on oncological outcomes of locally advanced bladder cancer with laparoscopic radical cystectomy: A matched-pair analysis in a multicenter cohort.
    Int J Urol. 2021 Mar 18. doi: 10.1111/iju.14557.
    PubMed    


  27. MIYAMOTO T, Miyake M, Toyoshima Y, Fujii T, et al
    Clinical outcomes after intravesical bacillus Calmette-Guerin for the highest-risk non-muscle-invasive bladder cancer newly defined in the Japanese Urological Association Guidelines 2019.
    Int J Urol. 2021 Mar 18. doi: 10.1111/iju.14545.
    PubMed     Abstract available


  28. TULLY KH, Reese SW, Cole AP, Noldus J, et al
    Temporal trends in the incidence of distant-stage bladder cancer among young individuals.
    Int J Urol. 2021 Mar 14. doi: 10.1111/iju.14550.
    PubMed    


  29. HUANG H, Yan B, Hao H, Shang M, et al
    Laparoscopic versus open radical cystectomy in 607 patients with bladder cancer: Comparative survival analysis.
    Int J Urol. 2021 Mar 13. doi: 10.1111/iju.14537.
    PubMed     Abstract available


  30. KANNO T
    Editorial Comment from Dr Kanno to Laparoscopic versus open radical cystectomy in 607 patients with bladder cancer: Comparative survival analysis.
    Int J Urol. 2021 Mar 13. doi: 10.1111/iju.14551.
    PubMed    


  31. KUBOTA M, Kanno T, Inoue T, Yamasaki T, et al
    Effect of optimal neoadjuvant chemotherapy on oncological outcomes of locally advanced bladder cancer with laparoscopic radical cystectomy: A matched-pair analysis in a multicenter cohort.
    Int J Urol. 2021 Mar 7. doi: 10.1111/iju.14533.
    PubMed     Abstract available


    February 2021
  32. INOKUCHI J, Kuroiwa K, Nishiyama H, Kojima T, et al
    Significance of the timing of ureteral ligation on prognosis during radical nephroureterectomy for upper urinary tract urothelial cancer.
    Int J Urol. 2021;28:208-214.
    PubMed     Abstract available


    November 2020
  33. NAKAGAWA T
    Lymph node dissection for bladder cancer: Current standards and the latest evidence.
    Int J Urol. 2020 Nov 3. doi: 10.1111/iju.14398.
    PubMed     Abstract available


  34. TANAKA H, Fujii Y
    Editorial Comment to Lymph node dissection for bladder cancer: Current standards and the latest evidence.
    Int J Urol. 2020 Nov 3. doi: 10.1111/iju.14419.
    PubMed    


  35. KOJIMA T
    Editorial Comment from Dr Kojima to Relationship between post-void residual urine volume, preoperative pyuria and intravesical recurrence after transurethral resection of bladder carcinoma.
    Int J Urol. 2020;27:1031.
    PubMed    


  36. YOSHIDA T, Matsuda T
    Editorial Comment from Dr Yoshida and Dr Matsuda to Relationship between post-void residual urine volume, preoperative pyuria and intravesical recurrence after transurethral resection of bladder carcinoma.
    Int J Urol. 2020;27:1030-1031.
    PubMed    


    September 2020
  37. TAOKA R, Matsuoka Y, Kohashiguchi K, Miura T, et al
    Impact of second transurethral resection on recurrence in patients with high-grade Ta bladder cancer.
    Int J Urol. 2020 Sep 28. doi: 10.1111/iju.14372.
    PubMed     Abstract available


  38. KHETRAPAL P
    Editorial Comment to Benefits of robotic cystectomy compared with open cystectomy in an Enhanced Recovery After Surgery program: A propensity-matched analysis.
    Int J Urol. 2020;27:788-789.
    PubMed    


    August 2020
  39. IWASAWA T, Niwa N, Matsumoto K, Komatsuda A, et al
    Reduced recurrence of low-risk non-muscle-invasive bladder cancer is associated with low urine-specific gravity.
    Int J Urol. 2020 Aug 13. doi: 10.1111/iju.14351.
    PubMed     Abstract available


    July 2020
  40. TANAKA H
    Editorial Comment to Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision.
    Int J Urol. 2020 Jul 21. doi: 10.1111/iju.14314.
    PubMed    


    June 2020
  41. WEINER AB, Pham MN, Isaacson DS, Ko OS, et al
    Predictors of use and overall survival for patients undergoing metastasectomy for bladder cancer in a national cohort.
    Int J Urol. 2020 Jun 26. doi: 10.1111/iju.14288.
    PubMed     Abstract available


  42. MATSUMOTO H, Shiraishi K, Azuma H, Inoue K, et al
    Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision.
    Int J Urol. 2020 Jun 21. doi: 10.1111/iju.14281.
    PubMed     Abstract available


  43. SHIN T
    Editorial Comment from Dr Shin to Frailty is significantly associated with the type of urinary diversion in patients with muscle-invasive bladder cancer.
    Int J Urol. 2020 Jun 4. doi: 10.1111/iju.14282.
    PubMed    


  44. ADOMI S, Fujita K, Yoshimura K, Uemura H, et al
    Editorial Comment from Dr Adomi et al. to Frailty is significantly associated with the type of urinary diversion in patients with muscle-invasive bladder cancer.
    Int J Urol. 2020 Jun 4. doi: 10.1111/iju.14284.
    PubMed    


    May 2020
  45. OKITA K, Hatakeyama S, Momota M, Soma O, et al
    Frailty is significantly associated with the type of urinary diversion in patients with muscle-invasive bladder cancer.
    Int J Urol. 2020 May 25. doi: 10.1111/iju.14263.
    PubMed     Abstract available


    March 2020
  46. MATSUMOTO H, Shiraishi K, Azuma H, Inoue K, et al
    Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper.
    Int J Urol. 2020 Mar 14. doi: 10.1111/iju.14210.
    PubMed     Abstract available


    February 2020
  47. ABE T
    Editorial Comment from Dr Abe to Oncological outcomes and recurrence patterns after laparoscopic radical cystectomy for bladder cancer: A Japanese multicenter cohort.
    Int J Urol. 2020 Feb 5. doi: 10.1111/iju.14193.
    PubMed    


  48. TANAKA H, Fujii Y
    Editorial Comment from Dr Tanaka and Dr Fujii to Oncological outcomes and recurrence patterns after laparoscopic radical cystectomy for bladder cancer: A Japanese multicenter cohort.
    Int J Urol. 2020 Feb 5. doi: 10.1111/iju.14194.
    PubMed    


    January 2020
  49. TANAKA H, Fukushima H, Kijima T, Nakamura Y, et al
    Feasibility and outcomes of selective tetramodal bladder-preservation therapy in elderly patients with muscle-invasive bladder cancer.
    Int J Urol. 2020 Jan 19. doi: 10.1111/iju.14179.
    PubMed     Abstract available


  50. KANNO T, Inoue T, Ito K, Okumura K, et al
    Oncological outcomes and recurrence patterns after laparoscopic radical cystectomy for bladder cancer: A Japanese multicenter cohort.
    Int J Urol. 2020 Jan 16. doi: 10.1111/iju.14182.
    PubMed     Abstract available


  51. HERR H
    Does asymptomatic bacteriuria affect the response to intravesical bacillus Calmette-Guerin?
    Int J Urol. 2020;27:72-74.
    PubMed     Abstract available


    December 2019
  52. KIKUCHI E, Hayakawa N, Fukumoto K, Shigeta K, et al
    Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer: Its definition and future therapeutic strategies.
    Int J Urol. 2019 Dec 3. doi: 10.1111/iju.14153.
    PubMed     Abstract available


    October 2019
  53. FUKUHARA H
    Editorial Comment from Dr Fukuhara to Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2019 Oct 11. doi: 10.1111/iju.14124.
    PubMed    


  54. MATSUMOTO H
    Editorial Comment from Dr Matsumoto to Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2019 Oct 6. doi: 10.1111/iju.14131.
    PubMed    


    September 2019
  55. NOHARA T, Kato Y, Nakano T, Nakagawa T, et al
    Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2019 Sep 11. doi: 10.1111/iju.14099.
    PubMed     Abstract available


  56. CHOO SH, Nishiyama H, Kitamura H, Chen CH, et al
    Practice pattern of non-muscle invasive bladder cancer in Japan, Korea and Taiwan: A Web-based survey.
    Int J Urol. 2019 Sep 11. doi: 10.1111/iju.14105.
    PubMed     Abstract available


    August 2019
  57. YOSHIDA T, Kates M, Fujita K, Bivalacqua TJ, et al
    Predictive biomarkers for drug response in bladder cancer.
    Int J Urol. 2019 Aug 1. doi: 10.1111/iju.14082.
    PubMed     Abstract available


    July 2019
  58. FUJIMURA T
    Current status and future perspective of robot-assisted radical cystectomy for invasive bladder cancer.
    Int J Urol. 2019 Jul 30. doi: 10.1111/iju.14076.
    PubMed     Abstract available


  59. TEISHIMA J, Matsubara A
    Editorial Comment to Current status and future perspective of robot-assisted radical cystectomy for invasive bladder cancer.
    Int J Urol. 2019 Jul 30. doi: 10.1111/iju.14086.
    PubMed    


  60. KOJIMA T
    Editorial Comment from Dr Kojima to Renal function after bladder-preserving therapy for patients with muscle-invasive bladder cancer: Results of selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, inductio
    Int J Urol. 2019 Jul 28. doi: 10.1111/iju.14074.
    PubMed    


  61. KOBAYASHI T
    Editorial Comment from Dr Kobayashi to Renal function after bladder-preserving therapy for patients with muscle-invasive bladder cancer: Results of selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induc
    Int J Urol. 2019 Jul 21. doi: 10.1111/iju.14075.
    PubMed    


  62. OSAWA T, Wei JT, Abe T, Kako Y, et al
    Development of the Japanese version of the health-related quality of life questionnaire for bladder cancer patients using the Bladder Cancer Index: A pilot study.
    Int J Urol. 2019 Jul 16. doi: 10.1111/iju.14073.
    PubMed    


  63. TOIDE M, Yokoyama M, Fujiwara M, Kijima T, et al
    Renal function after bladder-preserving therapy for patients with muscle-invasive bladder cancer: Results of selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and partial cyst
    Int J Urol. 2019 Jul 8. doi: 10.1111/iju.14054.
    PubMed    


    March 2019
  64. NAKAYAMA M, Ito Y, Hatano K, Nakai Y, et al
    Impact of sex difference on survival of bladder cancer: A population-based registry data in Japan.
    Int J Urol. 2019 Mar 27. doi: 10.1111/iju.13955.
    PubMed     Abstract available


  65. LEE A, Lee HJ, Huang HH, Ho H, et al
    Low-risk non-muscle-invasive bladder cancer: Further prognostic stratification into the "very-low-risk" group based on tumor size.
    Int J Urol. 2019 Mar 4. doi: 10.1111/iju.13913.
    PubMed     Abstract available


  66. ZACHOS I
    Editorial Comment to Low-risk non-muscle-invasive bladder cancer: Further prognostic stratification into the "very-low-risk" group based on tumor size.
    Int J Urol. 2019 Mar 4. doi: 10.1111/iju.13929.
    PubMed    


    February 2019
  67. YASUI M, Kawahara T, Takamoto D, Izumi K, et al
    Distribution of androgen receptor expression in the urinary bladder.
    Int J Urol. 2019;26:305-306.
    PubMed    


    January 2019
  68. KOIE T, Ohyama C, Makiyama K, Shimazui T, et al
    Utility of robot-assisted radical cystectomy with intracorporeal urinary diversion for muscle-invasive bladder cancer.
    Int J Urol. 2019 Jan 28. doi: 10.1111/iju.13900.
    PubMed     Abstract available


  69. TEISHIMA J, Matsubara A
    Editorial Comment to Utility of robot-assisted radical cystectomy with intracorporeal urinary diversion for muscle-invasive bladder cancer.
    Int J Urol. 2019 Jan 28. doi: 10.1111/iju.13906.
    PubMed    


  70. MIYATA Y, Matsuo T, Sakai H
    Editorial Comment from Dr Miyata et al. to Impact of serum sodium concentration on survival outcomes in patients with invasive bladder cancer without metastasis treated by cystectomy.
    Int J Urol. 2019 Jan 22. doi: 10.1111/iju.13893.
    PubMed     Abstract available


    December 2018
  71. HASHIMOTO T
    Editorial Comment from Dr Hashimoto to Impact of serum sodium concentration on survival outcomes in patients with invasive bladder cancer without metastasis treated by cystectomy.
    Int J Urol. 2018 Dec 16. doi: 10.1111/iju.13889.
    PubMed    


  72. NAKATA W, Yamamichi G, Tsujimura G, Tsujimoto Y, et al
    Impact of serum sodium concentration on survival outcomes in patients with invasive bladder cancer without metastasis treated by cystectomy.
    Int J Urol. 2018 Dec 2. doi: 10.1111/iju.13880.
    PubMed    


    November 2018
  73. MIYAKE M, Nakai Y, Hori S, Morizawa Y, et al
    Transient liver toxicity as a result of the oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2018 Nov 18. doi: 10.1111/iju.13856.
    PubMed    


    October 2018
  74. ADELOYE D, Harhay MO, Ayepola OO, Dos Santos JP, et al
    Estimate of the incidence of bladder cancer in Africa: A systematic review and Bayesian meta-analysis.
    Int J Urol. 2018 Oct 21. doi: 10.1111/iju.13824.
    PubMed     Abstract available


  75. MIYAKE M, Hori S, Owari T, Morizawa Y, et al
    Animal model of local tumor recurrence after resection using the murine MBT2 bladder cancer cell line in syngeneic C3H mice.
    Int J Urol. 2018 Oct 16. doi: 10.1111/iju.13834.
    PubMed    


    July 2018
  76. OHTAKA M, Kawahara T, Ishiguro Y, Sharma M, et al
    Expression of receptor activator of nuclear factor kappa B ligand in bladder cancer.
    Int J Urol. 2018 Jul 24. doi: 10.1111/iju.13756.
    PubMed    


  77. ZHANG D, Zhou C, Li Y, Gao L, et al
    Amyloid precursor protein is overexpressed in bladder cancer and contributes to the malignant bladder cancer cell behaviors.
    Int J Urol. 2018 Jul 18. doi: 10.1111/iju.13726.
    PubMed     Abstract available


  78. NAKAI Y, Inoue K, Tsuzuki T, Shimamoto T, et al
    Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A multicenter phase III study.
    Int J Urol. 2018 Jul 12. doi: 10.1111/iju.13718.
    PubMed     Abstract available


  79. YANG J, Zhang P, Zhou H, Feng S, et al
    Prospective, randomized controlled study of the preventive effect of fosfomycin tromethamine on post-transurethral resection of bladder tumor urinary tract infection.
    Int J Urol. 2018 Jul 12. doi: 10.1111/iju.13719.
    PubMed    


    March 2018
  80. MIYAZAKI J, Onozawa M, Takaoka E, Yano I, et al
    Bacillus Calmette-Guerin strain differences as the basis for immunotherapies against bladder cancer.
    Int J Urol. 2018 Mar 5. doi: 10.1111/iju.13538.
    PubMed     Abstract available


  81. TATSUGAMI K
    Editorial Comment to Prediction models for progression of non-muscle-invasive bladder cancer: A review.
    Int J Urol. 2018;25:218-219.
    PubMed    


    February 2018
  82. OTTO W, van Rhijn BW, Breyer J, Bertz S, et al
    Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naive stage T1 high-grade urothelial bladder cancer.
    Int J Urol. 2018 Feb 22. doi: 10.1111/iju.13532.
    PubMed     Abstract available


    December 2017
  83. FUJII Y
    Prediction models for progression of non-muscle-invasive bladder cancer: A review.
    Int J Urol. 2017 Dec 16. doi: 10.1111/iju.13509.
    PubMed     Abstract available


  84. OHNO Y
    Editorial Comment to High neutrophil-to-lymphocyte ratio predicts worse overall survival in patients with advanced/metastatic urothelial bladder cancer.
    Int J Urol. 2017 Dec 7. doi: 10.1111/iju.13506.
    PubMed    


    November 2017
  85. YANG X, Shi L, Yi C, Yang Y, et al
    Astrocyte elevated gene-1 promotes invasion and epithelial-mesenchymal transition in bladder cancer cells through activation of signal transducer and activator of transcription 3.
    Int J Urol. 2017 Nov 8. doi: 10.1111/iju.13486.
    PubMed     Abstract available


  86. TAN YG, Eu EWC, Huang HH, Lau WKO, et al
    High neutrophil-to-lymphocyte ratio predicts worse overall survival in patients with advanced/metastatic urothelial bladder cancer.
    Int J Urol. 2017 Nov 1. doi: 10.1111/iju.13480.
    PubMed     Abstract available


    July 2017
  87. SALUJA M, Gilling P
    Intravesical bacillus Calmette-Guerin instillation in non-muscle-invasive bladder cancer: A review.
    Int J Urol. 2017 Jul 25. doi: 10.1111/iju.13410.
    PubMed     Abstract available


  88. KOBATAKE K, Hayashi T, Black PC, Goto K, et al
    Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer.
    Int J Urol. 2017 Jul 22. doi: 10.1111/iju.13389.
    PubMed     Abstract available


  89. NASELLI A
    Editorial Comment to Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer.
    Int J Urol. 2017 Jul 21. doi: 10.1111/iju.13402.
    PubMed    


    March 2017
  90. SHIMIZU F, Muto S, Taguri M, Ieda T, et al
    Effectiveness of platinum-based adjuvant chemotherapy for muscle-invasive bladder cancer: A weighted propensity score analysis.
    Int J Urol. 2017 Mar 9. doi: 10.1111/iju.13324.
    PubMed     Abstract available


    February 2017
  91. INOUE K
    5-Aminolevulinic acid-mediated photodynamic therapy for bladder cancer.
    Int J Urol. 2017;24:97-101.
    PubMed     Abstract available


    January 2017
  92. ALIMI Q, Verhoest G, Kammerer-Jacquet SF, Mathieu R, et al
    Response to Re: Role of routine computed tomography scan in the oncological follow up of patients treated by radical cystectomy for bladder cancer.
    Int J Urol. 2017 Jan 13. doi: 10.1111/iju.13290.
    PubMed    


  93. MATSUMURA N, Nakamura Y, Kohjimoto Y, Nishizawa S, et al
    Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy.
    Int J Urol. 2017 Jan 9. doi: 10.1111/iju.13274.
    PubMed     Abstract available


    December 2016
  94. ALEVIZOPOULOS A, Tyritzis S, Leotsakos I, Anastasopoulou I, et al
    Role of coagulation factors in urological malignancy: A prospective, controlled study on prostate, renal and bladder cancer.
    Int J Urol. 2016 Dec 22. doi: 10.1111/iju.13271.
    PubMed     Abstract available


  95. BESIROGLU H
    Re: Role of routine computed tomography scan in the oncological follow up of patients treated by radical cystectomy for bladder cancer.
    Int J Urol. 2016 Dec 1. doi: 10.1111/iju.13269.
    PubMed    


    November 2016
  96. REIS LO
    Editorial Comment to Orthotopic mouse model of renal pelvic cancer using a human bladder cancer cell line.
    Int J Urol. 2016;23:963.
    PubMed    


    October 2016
  97. VIDAL A, Arnold N, Vartolomei MD, Kiss B, et al
    Oncological and functional outcomes of postoperative total parenteral nutrition after radical cystectomy in bladder cancer patients: A single-center randomized trial.
    Int J Urol. 2016 Oct 21. doi: 10.1111/iju.13228.
    PubMed     Abstract available


  98. HERMANS TJ, van de Putte EE, Horenblas S, van Rhijn BW, et al
    Extended pelvic lymph node dissection at radical cystectomy for bladder cancer improves survival: Results of a nationwide population-based study.
    Int J Urol. 2016 Oct 4. doi: 10.1111/iju.13227.
    PubMed    


    April 2016
  99. DAL MORO F, Zattoni F
    Lighting from the urethral cystoscope side: A novel technique to safely manage bowel division during intracorporeal robotic urinary diversion.
    Int J Urol. 2016;23:344-5.
    PubMed    


  100. JINZAKI M, Kikuchi E, Akita H, Sugiura H, et al
    Role of computed tomography urography in the clinical evaluation of upper tract urothelial carcinoma.
    Int J Urol. 2016;23:284-98.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: